LXRX — Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 103
- Website: https://www.lexpharma.com
Latest SEC filings for LXRX
- EFFECT — 2026-08-17
- S-8 — 2026-08-06
- SCHEDULE 13G/A — 2026-08-06
- S-3 — 2026-08-06
- 8-K — 2026-08-06
- 10-Q — 2026-08-06
- S-3 — 2026-08-06
- 10-Q — 2026-05-07
- 8-K — 2026-05-07
- 8-K — 2026-05-06
Latest LXRX news
- — Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy (seekingalpha_market)
- — Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today (fool.com)
- — Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of “Hold” from Brokerages
- — This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday (benzinga.com)
Educational tool only — not investment advice.